Flutamide-induced hepatotoxicity during treatment of acne - A case report;Hepatotoxicidade pela flutamida em paciente sob tratamento para acne - Relato de caso

Anais Brasileiros de Dermatologia

Volumn 80, Issue 4, 2005, Pages 381-384

  Duques De Amorim, Maria De Fátima ^a,b,g   Duques De Amorim, Paulo ^e   Dias De Amorim, Waldir Pedrosa ^c   Ramalho De Vasconcelos, Juliana ^f   Duques, Pedro ^d  

^a HULW   (Brazil)

^b FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^c Endocenter PB ^*

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e Mandaqui Hospital   (Brazil)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g Endocenter Unidade do Figado e Gastroenterologia   (Brazil)

Author keywords

Acne vulgaris; Flutamide; Hepatitis, toxic

Indexed keywords

AMINOTRANSFERASE; ANTIANDROGEN; FLUTAMIDE;

ACNE; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HIRSUTISM; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MONITORING; PROSTATE CANCER; RISK BENEFIT ANALYSIS;

EID: 26244454933     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0365-05962005000400009     Document Type: Article

References (15)

1. Shaw JC. Acne: effect of hormones on pathogenesis and management. Am J Clin Dermatol. 2002;3:571-8.
2. García Cortés M, Andrade RJ, Lucena MI, Sánchez Martínez H, Fernández MC, Ferrer T, et al. Flutamide-induced hepatotoxicity: report of a case series. Rev Esp Enferm Dig Jul. 2001;93:423-32.
3. Ozono S, Yamaguchi A, Mochizuki H, Kawakami T, Fujimoto K, Otani T, et al. Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer. Prostate Cancer Prostatic Dis. 2002;5:128-31.
4. Apablaza HMS, Varas CJ. Hepatitis aguda inducida por flutamida. Rev Chil Obstet Ginecol. 2001;66:437-8.
5. Gaedike CA, Borini O, Cunha ACF, Medeiros JM, Filho OG, Corrêa EBD. Hepatite colestática secundária à administraç ão de flutamida. In: XXXVI Congresso Brasileiro de Gastroenterologia. 2000; Foz do Iguaçu - PR. GED Gastroenterol Endosc Dig. 2000;19:Suppl. 2:43S. [Abstract 269].
6. Maria VAJ, Vitorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26:664-9.
7. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology. 2001; 33:308-10.
8. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol. 2003;12:189-92.
9. Bakos L, Rossi V, Filgueira AL, Bakos RM. Flutamida no tratamento da acne. An Bras Dermatol. 1998;73:83-6.
10. Lee HW, Chung JC Lee KS, Kim KC, Lee KS, Chon CY, et al. A case of flutamide-induced acute cholestatic hepatitis- a case report. Yonsei Med J. 1996;37:225-9.
11. Munekado K, Kazumi K, Osamu U, Akira F, Masahiro N, Shigekl T, et al. Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: A preliminary study. Int J Urol. 2002;9:42.
12. Silva LC. Importância e uso clínico dos marcadores virais e sorológicos. In: Silva, L. C. Hepatites agudas e crônicas. São Paulo: Sarvier; 2003. p.60-81.
13. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol. 1996; 155:209-12.
14. Pu YS, Liu CM, Kao JH, Chen J, Lai MK. Antiandrogen hepatotoxicity in patients with chronic viral hepatitis. Eur Urol. 1999;36:293-7.
15. ANVISA (Agência Nacional de Vigilância Sanitária), [sitio na internet], [citado 2004 nov 17] Disponível em: http://www.anvisa.gov.br.